

1 **AOAC SMPR XXXX.XXX; version 1.6; August 26, 2021**

2 Standard Method Performance Requirements (SMPRs®) for A1 and A2 beta casein in Infant Formulas
3 and Adult Nutritionals

4 Intended Use: Method Dispute Resolution

5 **1. Applicability**

6 Measure the amount of bovine “A2-type” β -casein and “A1-type” β -casein found in all forms of infant,
7 adult, and /or pediatric formulas (powders, ready-to-feed liquids, and liquid concentrates).

8 **2. Analytical Technique**

9 Any analytical technique(s) that measures the analyte(s) of interest and meets the following method
10 performance requirements is/are acceptable.

11 **3. Definitions**

12 Infant formula.—Breast-milk substitute specially manufactured to satisfy, by itself, the nutritional
13 requirements of infant during the first months of life up to the introduction of appropriate
14 complementary feeding (Codex Standard 72-1981) Infant Formula and Formulas for Special Medical
15 Purposes – 0–12 month of age; Follow-Up Formula – from 6–12 months and for young children; Young
16 Children – 12–36 months of age; Foods for Special Medical Purposes Nutritionally complete specially
17 formulated food for adults, consumed in liquid form, which may constitute the sole source of
18 nourishment (AOAC Stakeholder Panel on Infant Formula and Adult Nutritionals; 2010). Made from any
19 combination of milk, soy, rice, whey, hydrolyzed protein, starch and amino acids, with and without
20 intact protein.

21 **Bovine β -casein**—>sp|P02666|16-224|CASB_BOVIN Beta-casein OS=Bos taurus OX=9913
22 GN=CSN2 PE=1 SV=2
23 RELEELNVPGEIVESLSSEESITRINKKIEKFQSEEQQQTDELQDKIHPPFAQTQSLVYPPFGPI P NSLPQNI PPL
24 TQTPVVVPPFLQPEVMGVSKVKEAMAPKHKEMPFKYPVEPFTEQSLLTLDVENLHLPLPLLQSWMHQPHQPLPPT
25 VMFPPQSVLSLSQSKVLPVPQKAVPYQQRDMPIQAFLLYQEPVLGPVVRGPFPIIV
26

27 This sequence shown represents the secreted, full-length bovine β -casein after signal peptide removal.

28 BCM-7: Beta casomorphin peptide, released upon digestion of β -casein protein in human gut.

29 Sequence: YPPFGPI

30 “A1 type” β -casein—Full-length variants of β -casein that have the potential to release the BCM-7
31 peptide under gut digestion (i.e. that contain histidine at amino acid position 67), including e.g.
32 phosphorylated and glycosylated proteoforms.

33 “A2 type” β -casein— Full-length variants of β -casein that have a reduced potential to release the BCM-7
34 peptide under gut digestion (i.e. that contain proline at amino acid position 67), including e.g.
35 phosphorylated and glycosylated proteoforms.

36 Limit of detection (LOD) — The lowest concentration or mass of analyte in a test sample that can be
37 distinguished from a true blank sample at a specified probability level.

38 Limit of quantitation (LOQ) — The lowest level of analyte in a test sample that can be quantified at a
39 specified level of precision.

40 Recovery. — Fraction or percentage of analyte that is measured when the test sample is analyzed using
41 the entire method.

42 Repeatability. —Variation arising when all efforts are made to keep conditions constant by using the
43 same instrument and operator (in the same laboratory) and repeating during a short time period.
44 Expressed as the repeatability standard deviation (SD_r); or % repeatability relative standard deviation
45 (%RSD_r).

46 Reproducibility. —Variation arising when identical test materials are analyzed in different laboratory by
47 different operators on different instruments. The standard deviation or relative standard deviation
48 calculated from among-laboratory data. Expressed as the reproducibility standard deviation (SD_R); or %
49 reproducibility relative standard deviation (%RSD_R).

50 **4. Method Performance Requirements See Table 1.**

51 Table 1. Method performance requirements

Analytical range	1-500 mg/100g ^b
Limit of Quantitation (LOQ)	1 mg/100g (0.001%) ^b
Recovery, %	80-110
Repeatability (RSD _r)	1-50 mg/100g ^b : 15% >50 mg/100g ^b : 10%
Reproducibility (RSD _R)	1-50 mg/100g ^b : 20% >50 mg/100g ^b : 15%

52 a. Concentrations apply to: (a) ‘ready-to-feed’ liquids “as is”; (b) reconstituted powders (25 g into
53 200 g water).

54 b. mg/100 g reconstituted final product

55 **5. System Suitability Tests and/or Analytical Quality Control**

56 Suitable methods will include blanks, and appropriate check standards.

57 **6. Reference and Harmonization Materials**

58 Refer to Annex F: Development and Use of In-House Reference Materials in Appendix F: Guidelines for
59 Standard Method Performance Requirements, 21st Ed. of the Official Methods of Analysis of AOAC
60 INTERNATIONAL (2019). Available at [http:// www.eoma.aoc.org/app_f.pdf](http://www.eoma.aoc.org/app_f.pdf)

61 **7. Validation Guidance**

62 Recommended level of validation: AOAC Official Methods of AnalysisSM. Method developers are
63 responsible for assessing interferences with the method. Protein or peptide standard material
64 characterization, by appropriate methodology, should be described within the method submission.
65 Examples may include protein content, protein purity (PAGE, other), and isoform characterization for
66 “A2-type” β-casein and “A1-type” β-casein.

67 **8. Maximum Time-to-Results**

68 None